Friday, April 17, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Reflecting on healthcare trends with Dr. Lynn Webster

Dr. Lynn Webster is a Senior Fellow at the Center for U.S. Policy, specializing in healthcare policy and patient care. He serves as the Associate Editor, Special Populations Section, Pain Medicine; Chief Medical Officer for PainScript; Author of the award-winning book, The Painful Truth Documentary; and Co-Producer of It Hurts Until You Die.

With extensive board certifications in pain medicine, addiction medicine, and anesthesiology, Dr. Webster’s contributions to healthcare have been groundbreaking. His role as the principal investigator for the National Institute on Drug Abuse (NIDA) award 5RC2DA028984-02, under the American Recovery and Reinvestment Act of 2009, highlights his dedication to research in pain management and addiction.

One of Dr. Webster’s notable achievements is the development of the Opioid Risk Tool, a critical resource for healthcare professionals dealing with pain and addiction. This tool, available at link, underscores his commitment to improving patient care and health outcomes.

The Opioid Risk Tool he developed can be found at the following link: https://nida.nih.gov/sites/default/files/opioidrisktool.pdf

#DEA #pain #addiction #health #policy #patient #care #research

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

Policy Shift in Peptide Regulation

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide has moved beyond its original indication and now sits at the center of a widening set of clinical questions: cardiovascular risk, kidney disease progression, and even neurodegeneration. The question is no longer whether the drug lowers glucose or reduces weight—it does—but how far those effects extend across systems, and whether evidence from one population can be translated into another without distortion. Large, well-powered trials have produced consistent signals, yet those signals are now being applied in contexts that were...

Read more

Join Our Newsletter!